Sulfated Galactofucan from Sargassum Thunbergii Attenuates Atherosclerosis by Suppressing Inflammation Via the TLR4/MyD88/NF-κB Signaling Pathway

Cardiovasc Drugs Ther. 2024 Feb;38(1):69-78. doi: 10.1007/s10557-022-07383-3. Epub 2022 Oct 4.

Abstract

Purpose: Sulfated galactofucan (SWZ-4), which was extracted from Sargassum thunbergii, has recently been reported to show anti-inflammatory and anticancer properties. The present study aimed to evaluate whether SWZ-4 attenuates atherosclerosis in apolipoprotein E-knockout (ApoE-KO) mice by suppressing the inflammatory response through the TLR4/MyD88/NF-κB signaling pathway.

Methods: Male ApoE-KO mice were fed with a high-fat diet for 16 weeks and intraperitoneally injected with SWZ-4. RAW246.7 cells were treated with lipopolysaccharide (LPS) and SWZ-4. Atherosclerotic lesions were measured by Sudan IV and oil red O staining. Serum lipid profiles, inflammatory cytokines, and mRNA and protein expression levels were evaluated.

Results: SWZ-4 decreased serum TNF-α, IL-6 and IL-1 levels, but did not reduce blood lipid profiles. SWZ-4 downregulated the mRNA and protein expression of TLR4 and MyD88, reduced the phosphorylation of p65, and attenuated atherosclerosis in the ApoE-KO mice (p < 0.01). In LPS-stimulated RAW 264.7 cells, SWZ-4 inhibited proinflammatory cytokine production and the mRNA expression of TLR4, MyD88, and p65 and reduced the protein expression of TLR4 and MyD88 and the phosphorylation of p65 (p < 0.01).

Conclusion: These results suggest that SWZ-4 may exert an anti-inflammatory effect on ApoE-KO atherosclerotic mice by inhibiting the TLR4/MyD88/NF-κB signaling pathway in macrophages and therefore may be a treatment for atherosclerosis.

Keywords: Anti-inflammatory; Atherosclerosis; Plant extracts; Sargassum; TLR4-MyD88-NF-κB.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Apolipoproteins E / genetics
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / pathology
  • Atherosclerosis* / prevention & control
  • Fucose*
  • Galactose*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Inflammation / prevention & control
  • Lipopolysaccharides / pharmacology
  • Male
  • Mice
  • Mice, Knockout
  • Myeloid Differentiation Factor 88 / genetics
  • Myeloid Differentiation Factor 88 / metabolism
  • Myeloid Differentiation Factor 88 / pharmacology
  • NF-kappa B / metabolism
  • RNA, Messenger / therapeutic use
  • Sargassum* / genetics
  • Sargassum* / metabolism
  • Signal Transduction
  • Sulfates / metabolism
  • Sulfates / pharmacology
  • Sulfates / therapeutic use
  • Toll-Like Receptor 4 / metabolism

Substances

  • NF-kappa B
  • Myeloid Differentiation Factor 88
  • Toll-Like Receptor 4
  • galactofucan
  • Lipopolysaccharides
  • Sulfates
  • Anti-Inflammatory Agents
  • Apolipoproteins E
  • RNA, Messenger
  • Fucose
  • Galactose